57113-91-4

Basic information

• Product Name: Methyl 2-amino-3-nitrobenzoate
• Synonyms: 3-Nitro-anthranilic Acid Methyl Ester;2-(Methoxycarbonyl)-6-nitroaniline, 2-Amino-3-(methoxycarbonyl)nitrobenzene, Methyl 3-nitroanthranilate;2-AMINO-3-NITROBENZOIC ACID METHYL ESTER;METHYL 2-AMINO-3-NITROBENZOATE;RARECHEM AH CK 0023;Methyl 3-nitroanthranilate;Methyl 2-amino-3-nitrobenzoate 95%;Benzoic acid, 2-amino-3-nitro-, methyl ester
• CAS NO: 57113-91-4
• Molecular Formula: C₈H₈N₂O₄
• Molecular Weight: 196.16
• EINECS: 1312995-182-4
• Product Categories: Amines;Intermediates & Fine Chemicals;Pharmaceuticals;Drug Intermediates;Aromatics;Aromatic Esters;Benzoic acid
• Mol File: 57113-91-4.mol
• Article Data: 21

Chemical Properties

• Melting Point: 97-98°C
• Boiling Point: 340.1 °C at 760 mmHg
• Flash Point: 159.5 °C
• Appearance: /
• Density: 1.386 g/cm³
• Vapor Pressure: 8.82E-05mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO, Ethyl Acetate
• PKA: -2.80±0.25(Predicted)
• CAS DataBase Reference: Methyl 2-amino-3-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-amino-3-nitrobenzoate(57113-91-4)
• EPA Substance Registry System: Methyl 2-amino-3-nitrobenzoate(57113-91-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 57113-91-4(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

An intermediate in the preparation of Candesartan.

InChI:InChI=1/C8H8N2O4/c1-14-8(11)5-3-2-4-6(7(5)9)10(12)13/h2-4H,9H2,1H3

Upstream product

• 67-56-1 methanol 
• 606-18-8 3-nitroanthranilic acid 
• 136918-14-4 phthalimide 
• 96385-50-1 3-nitrophthalamide 
• 73833-13-3 acid chloride of 1-methylhydrogen-3-nitrophthalate 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 
• 603-11-2 3-nitrophthalic acid 
• 13365-26-9 dimethyl 3-nitrophthalate 
• 134-20-3 2-carbomethoxyaniline 
• 112656-95-8 7-nitroindoline-2,3-dione 
• 88-74-4 2-nitro-aniline 
• 17122-60-0 2-(N-hydroxyimino)-N-(2-nitrophenyl)acetamide 
• 77-78-1 dimethyl sulfate 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 107582-20-7 2,3-diaminobenzoic acid methyl ester 
• 313278-90-9 methyl 2-N-(trifluoroacetyl)amino-3-nitrobenzoate 
• 936939-62-7 2-amino-3-nitrobenzoic acid sodium salt 
• 5337-09-7 2-bromo-3-nitro-benzoic acid methyl ester 
• 1442660-35-6 methyl 2,3-diphenylquinoxaline-5-carboxylate 
• 1438559-38-6 phenyl(quinoxalin-5-yl)methanone 
• 1442660-06-1 quinoxalin-5-yl(o-tolyl)methanone 
• 1442660-07-2 quinoxalin-5-yl(m-tolyl)methanone 
• 1442660-08-3 quinoxalin-5-yl(p-tolyl)methanone 
• 1442660-09-4 (4-(tert-butyl)phenyl)(quinoxalin-5-yl)methanone 
• 1442660-10-7 (3,5-dimethylphenyl)(quinoxalin-5-yl)methanone 
• 1442660-11-8 (4-methoxyphenyl)(quinoxalin-5-yl)methanone 
• 1442660-12-9 (3-methoxyphenyl)(quinoxalin-5-yl)methanone 
• 1442660-13-0 (3,4-dimethoxyphenyl)(quinoxalin-5-yl)methanone 

Relevant articles and documents

Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells

4’-((2-Propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid derived from telmisartan was identified as lead for the design of cell death modulators. In this study, we evaluated the efficacy of telmisartan itself and other sartans in combination with imatinib against K562-resistant cells. The findings were directly used to further optimize the lead structure. Telmisartan and candesartan cilexetil represented the most effective sartans, thus the influence of carboxyl/methyl carboxylate groups at positions 7 (compounds 6, 7) or 4 (compounds 12–14) at the benzimidazole core was studied. Additionally, according to the results of a former structure-activity study, telmisartan was transformed to the related amide (1). Telmisartan amide 1, as well as the esters 6 and 12 markedly sensitized the resistant CML cells to imatinib treatment. Correlation with their potency to activate PPARγ is not given. Candesartan cilexetil, telmisartan and 1 showed the profile of partial agonists at PPARγ with EC50 values of 4.2, 4.3 and 9.1 μM, respectively, while 6 and 12 caused only marginal intrinsic activation at 10 μM (Amax = 22% and 13%). However, the repression of the STAT5 phosphorylation relates with the possibility to sensitize K562-resistant CML cells to imatinib treatment. It is worth mentioning that all compounds were per se non-cytotoxic at relevant concentrations.

A 2 - ethoxy benzimidazole - 7 - carboxylic acid methyl ester

The invention discloses a synthesis method of 2-ethoxy benzimidazole-7-carboxylic acid methyl ester. The problem that an existing process is not high in content and is very low in yield is solved. According to the synthesis method, 3-nitryl phthalic acid is used as a raw material, rearrangement is performed in a water solution after methyl esterification, acylation and re-nitridation, then tin powder is adopted to perform reduction and loop closing so as to obtain the 2-ethoxy benzimidazole-7-carboxylic acid methyl ester. By the adoption of the synthesis method, produced impurities are very little, the content is high, and the yield is also high.

ANTI-MALIGNANT TUMOR AGENT COMPOSITION

To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.